Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Total Current Liabilities data on file, last reported at $125.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 68.9% year-over-year to $125.0 million in Q1 2026; TTM through Mar 2026 was $125.0 million, a 68.9% increase from a year earlier, with the FY2025 full-year figure at $132.0 million, up 54.03% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $125.0 million, down from $132.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for PHAT reached as high as $132.0 million in Q4 2025 and fell as low as $11.4 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $55.2 million across 5 years, with a median of $43.5 million in 2024.
• Across the five-year window, Total Current Liabilities slumped 72.1% in 2022 and soared 200.9% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $26.2 million in 2022, then soared by 47.81% to $38.8 million in 2023, then soared by 121.06% to $85.7 million in 2024, then surged by 54.03% to $132.0 million in 2025, then fell by 5.3% to $125.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $125.0 million in Q1 2026, $132.0 million in Q4 2025, and $93.1 million in Q3 2025.